drugset
drugset / Trial / NCT03335020

Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease

NCT03335020 ↗

Phase 1 Withdrawn Mayo Clinic
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The researchers are trying to see whether contrast-enhanced ultrasonography, shear wave elastography, strain imaging, and 3-D volume ultrasonography improves arterial wall visualization and identifies arterial elastic properties among individuals with fibromuscular dysplasia (FMD), atherosclerosis, personal history of spontaneous coronary artery dissections (SCAD), or personal history of segmental arterial mediolysis (SAM) that may be different compared to those without the aforementioned conditions.

Timeline

Start
2018-04-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lumason Diagnostic / imaging agent — Intravenous

Indications

atherosclerosis fibromuscular dysplasia idiopathic spontaneous coronary artery dissection segmental arterial mediolysis